New call-to-action


See all



How ResMed’s Sleep Solutions Are Powering The Company’s Growth

Jordan Baird

Jordan Baird is the head ASR Wealth Advisers client services desk and has been with the organisation since 2017. He first started investing in his early years. While he believes that investors should leave no stone unturned he has a particular interest in trading based on broad macroeconomic trends along with specific analysis of innovative up-and-coming companies.

ResMed (ASX: RMD) is a medical equipment company that focuses on treatments for sleep apnea, COPD, and other chronic respiratory diseases. Their products aim to serve the unpenetrated sleep and respiratory care market, with the result of keeping people out of the hospital. In the past 12 months, their products have changed 15 million lives and improved 90 million more through their out-of-hospital care network. Despite this success, management is still striving to improve 250 million lives in 2025, which would drive significant revenue growth if realised. ResMed is an $18B company that declared $2.6bn in revenue for FY19.

ResMed S9 Autoset to Treat Sleep Apnea (Credit: Sleep Right Australia)

The company’s product

ResMed has four main businesses across sleep, respiratory care, software as a service (SaaS) solutions, and digital technology products. Since sleep is one of ResMed’s most successful businesses and has the greatest growth prospects, this is the business unit we will focus on. Sleep-disordered breathing is more than 80% undiagnosed and is highly prevalent in conjunction with other chronic conditions. For every 100 U.S. adults, 4 of them are aware of their sleep apnea condition, while 22 suffer from it without realising that their condition can be treated.

ResMed has several masks and devices to aid in curing this ailment. However, this is not enough, since the majority of suffers are not even aware they have the condition. Effective marketing around sleep apnea awareness will be essential in treating the condition. As such, ResMed is currently having a sleep research joint venture with Verily to unlock more holistic insights about sleep apnea and the value of treating it. When people are aware of how sleep disorder impacts their breathing and affects their lives, people will be more willing to purchase ResMed’s solutions. This promises to unlock much larger SAAS revenue streams for ResMed, helping drive significant value creation for shareholders. Since technology improves health outcomes, the company may be able to tap into additional government subsidies to drive growth in key markets.


ResMed concentrates on opportunities in sleep apnea, COPD, other major chronic conditions, whilst caring for patients with SaaS solutions outside hospitals. Their main source of growth is through greater market penetration, the realisation of which will be dependent on effective sales and marketing. By utilising tech-driven integrated care, ResMed can drive superior patient outcomes and experiences.




This article has been prepared by the Australian Stock Report Pty Ltd (AFSL: 301 682. ABN: 94 106 863 978)

(“ASR”). ASR is part of Amalgamated Australian Investment Group Limited (AAIG) (ABN: 81 140 208 288 Level 13, 130 Pitt Street, Sydney NSW 2000).

This article is provided for informational purpose only and does not purport to contain all matters relevant to any particular investment or financial instrument. Any market commentary in this communication is not intended to constitute “research” as defined by applicable regulations. Whilst information published on or accessed via this website is believed to be reliable, as far as permitted by law, we make no representations as to its ongoing availability, accuracy or completeness. Any quotes or prices used herein are current at the time of preparation. This document and its contents are proprietary information and products of our firm and may not be reproduced or otherwise disseminated in whole or in part without our written consent unless required to by judicial or administrative proceeding. The ultimate decision to proceed with any transaction rests solely with you. We are not acting as your advisor in relation to any information contained herein. Any projections are estimates only and may not be realised in the future.

ASR has no position in any of the stocks mentioned.

New call-to-action